Mrs Kami Lessord Golembeski, OTR/L | |
522 Vermont Route 30, Bondville, VT 05340-9719 | |
(802) 353-3810 | |
Not Available |
Full Name | Mrs Kami Lessord Golembeski |
---|---|
Gender | Female |
Speciality | Occupational Therapist - Neurorehabilitation |
Location | 522 Vermont Route 30, Bondville, Vermont |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1568856623 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
225XN1300X | Occupational Therapist - Neurorehabilitation | 072.0000271 (Vermont) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mrs Kami Lessord Golembeski, OTR/L 522 Vermont Route 30, Bondville, VT 05340-9719 Ph: (802) 353-3810 | Mrs Kami Lessord Golembeski, OTR/L 522 Vermont Route 30, Bondville, VT 05340-9719 Ph: (802) 353-3810 |
News Archive
"Institutional donor aid in 2010 was at its highest-ever level - US$16.7 billion - but so were aid costs," according to preliminary estimates in the annual report of the international aid watchdog Development Initiatives released on Wednesday, IRIN reports.
It was also classified as a "Variant of Concern" (VOC B.1.1.7) in December 2020. First discovered in Kent, United Kingdom, in September 2020, this new variant has since been found in more than 29 countries across the globe, including the USA.
South Australian researchers working with Oracle Cloud technology and vaccine technology developed by local company Vaxine Pty Ltd are testing a vaccine candidate against the SARS-CoV-2 coronavirus responsible for the COVID-19 pandemic.
Vice President Joe Biden and British Deputy Prime Minister Nick Clegg recently said the U.S. and Britain would provide "'sustained long-term' support to Pakistani flood victims," Agence France-Presse reports.
Cara Therapeutics, Inc. today announced positive data in a Phase II proof-of-concept clinical trial of its peripherally-restricted kappa opioid agonist, CR845. The 46 patient Phase II, multi-center, double-blind, placebo-controlled study was conducted at eight hospitals in the United States and evaluated the efficacy and safety of CR845 in women following laparoscopic-assisted hysterectomy.
› Verified 3 days ago